Biotech entity
Medtronic Plc is most often covered alongside MiniMed Group Inc., which appears in 2 of these 3 stories. Each story carries 1.7 original sources on average, compared with 4.1 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 141-day span. The busiest single day carried 2.
Last mentioned: Jul 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Medtronic Plc is most often covered alongside MiniMed Group Inc., which appears in 2 of these 3 stories. Each story carries 1.7 original sources on average, compared with 4.1 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 141-day span. The busiest single day carried 2. ipo accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. The average consequence score is 6.3, matching the 6.3 beat baseline for this window. Medtronic Plc appears in 3 tracked Biotech stories published from March 6, 2026 through July 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 422 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Medtronic Plc. Shared-story counts are live from our verified record — not editorial picks.
Market Debut
MiniMed begins trading as an independent entity on the US exchange.
IPO Pricing
MiniMed prices 28 million shares at $20.00 per share, raising $560 million.
Analyst Debate
Market analysts debate the valuation of the diabetes unit amid competitive pressures.
Initial Filing
Medtronic's diabetes unit MiniMed seeks up to $784 million in U.S. IPO.
IPO Filing
MiniMed Group Inc. files S-1 registration statement for a US initial public offering.
Strategic Review
Medtronic announces intent to spin off its diabetes business unit to focus on core medtech.
Medtronic and Apollo Hospitals join forces to deploy an 11-bed advanced ICU in Hyderabad, aiming to harness real-world clinical data that can refine monitoring technologies. The collaboration could accelerate regulatory strategies and set a precedent for co-development between medtech and healthcare providers.
Source: indiagazette.com
Medtronic’s diabetes subsidiary, MiniMed Group Inc., has priced its initial public offering at $20.00 per share, successfully raising $560 million. The offering of 28 million shares comes in below initial valuation targets but marks a significant strategic pivot for parent company Medtronic plc.
Source: finanznachrichten.de · rttnews.com
Medtronic has successfully spun off its diabetes management business, MiniMed Group Inc., raising $560 million in a US IPO. Despite the significant capital raise, the offering priced below the initial marketed range, reflecting investor scrutiny of the competitive diabetes technology landscape.
Source: Bloomberg · health.economictimes.indiatimes.com
Medtronic Plc is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
